Ameritas Investment Partners’s Sarepta Therapeutics SRPT Stock Holding History

Ameritas Investment Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,794	Closed	-$321K	–	3207
2025 Q2	$321K	Hold	18,794	–	–	0.01%	1029
2025 Q1	$1.2M	Sell	18,794 -338	-2%	-$35.6K	0.04%	542
2024 Q4	$2.33M	Sell	19,132 -433	-2%	-$53.1K	0.08%	272
2024 Q3	$2.44M	Sell	19,565 -540	-3%	-$74.7K	0.08%	263
2024 Q2	$3.18M	Buy	+20,105	New	+$2.58M	0.11%	170
2018 Q2	–	Sell	-5,161	Closed	-$382K	–	3059
2018 Q1	$382K	Hold	5,161	–	–	0.02%	818
2017 Q4	$287K	Hold	5,161	–	–	0.01%	901
2017 Q3	$207K	Buy	5,161 +600	+13%	+$24K	0.01%	1050
2017 Q2	$154K	Buy	4,561 +271	+6%	+$8.82K	0.01%	1196
2017 Q1	$127K	Buy	+4,290	New	+$133K	0.01%	1291
2016 Q4	–	Sell	-3,690	Closed	-$227K	–	1275
2016 Q3	$227K	Buy	+3,690	New	+$112K	0.01%	961

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ameritas Investment Partners's SRPT Position: Q3 2025 in Review

Ameritas Investment Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 18,794 shares — an estimated $321K sold.

Ameritas Investment Partners first reported a position in SRPT in Q3 2016 and held it in 11 quarters. The position peaked at $3.18M in Q2 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Ameritas Investment Partners reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Ameritas Investment Partners sold 18,794 Sarepta Therapeutics shares in Q3 2025, an estimated $321K.
Ameritas Investment Partners first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 11 quarters.
Ameritas Investment Partners's Sarepta Therapeutics position peaked at $3.18M in Q2 2024.
320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Ameritas Investment Partners's 13F filing for Q3 2025, filed 10 Nov 2025.